Related references
Note: Only part of the references are listed.Recent progress in TGF-β inhibitors for cancer therapy
Cheng-Yi Huang et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
K. S. Tewari et al.
ANNALS OF ONCOLOGY (2021)
Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials
J. Gulley et al.
ANNALS OF ONCOLOGY (2021)
SHR-1701, a novel bifunctional anti-PD-L1/TGF-βRII agent, for pretreated recurrent/refractory (r/r) gastric cancer (GC): Data from a first-in-human phase I study
D. Liu et al.
ANNALS OF ONCOLOGY (2021)
SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
J. Feng et al.
ANNALS OF ONCOLOGY (2021)
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M. O'Malley et al.
GYNECOLOGIC ONCOLOGY (2021)
Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study
Hyun Chung et al.
GYNECOLOGIC ONCOLOGY (2021)
Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.
Julius Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.
Meiqi Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
Ho-Jae Lee
JOURNAL OF CANCER PREVENTION (2020)
Global elimination of cervical cancer as a public health problem
Marc Brisson et al.
LANCET ONCOLOGY (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Contextual determinants of TGFβ action in development, immunity and cancer
Charles J. David et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari et al.
LANCET (2017)
Targeting TGF-β Signaling for Therapeutic Gain
Rosemary J. Akhurst
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
TGF-β Tumor Suppression through a Lethal EMT
Charles J. David et al.
CELL (2016)
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
Stergios Boussios et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
A. Marijne Heeren et al.
MODERN PATHOLOGY (2016)
Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
Ryo Kitagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
High and Interrelated Rates of PD-L1(+)CD14(+) Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer
A. Marijne Heeren et al.
CANCER IMMUNOLOGY RESEARCH (2015)
TGFβ Receptor 1: An Immune Susceptibility Gene in HPV-Associated Cancer
Chaya Levovitz et al.
CANCER RESEARCH (2014)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Transforming growth factor-β signal transduction in angiogenesis and vascular disorders
P Bertolino et al.
CHEST (2005)
Share Paper
